Drug intelligence / Profile preview

Pan-beta coronavirus vaccine

Development stage: Preclinical
Lead developer: Hawaii Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

The Pan-beta coronavirus vaccine is a recombinant subunit vaccine candidate being developed by Hawaii Biotech. It is designed to provide broad-spectrum protection against multiple viruses within the *Betacoronavirus* genus, specifically targeting SARS-CoV, MERS-CoV, and SARS-CoV-2. The vaccine utilizes recombinant protein antigens derived from conserved regions of these viruses to elicit a cross-reactive immune response. This approach aims to provide a proactive defense against existing and potentially emerging beta-coronaviruses by focusing on shared antigenic targets across the viral family.

Other names: Hawaii Biotech pan-beta coronavirus vaccine

Beyond the preview

Go deeper on Pan-beta coronavirus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pan-beta coronavirus vaccine.

Explore the full profile